Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain, Postoperative 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Biphenotypic, Acute 1Leukemia 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1

Interventions

Filgrastim 9Cytarabine 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 6Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cladribine 5Mitoxantrone 4Methotrexate 4Cyclophosphamide 4Melphalan 3Injections 3Cyclosporine 3Biopsy 3venetoclax 2revumenib 2pegylated granulocyte colony-stimulating factor 2X-Rays 2Trimethoprim, Sulfamethoxazole Drug Combination 2Tacrolimus 2Specimen Handling 2Idarubicin 2Decitabine 2Daunorubicin 2Clofarabine 2Busulfan 2Bone Marrow Transplantation 2quizartinib 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Biphenotypic, Acute × Midazolam × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡